- Olaparib Plus Durvalumab and Bevacizumab Provides Durable Survival in Non-Germline, BRCA+ Relapsed Ovarian Cancer.
- Seymour C.
- OncLive. 2022 Dec 4.
- Research news
- Free Full Text
•• Identifier: NCT02734004: A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA). (ClinicalTrials.gov . Accessed 2022 Dec 4.)
- Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
- Inderjeeth AJ, Topp M, Sanij E, Castro E, Sandhu S.
- Cancers (Basel). 2022 Nov 30;14(23):5922. doi: 10.3390/cancers14235922.
- Review
- Free Full Text
- Immediate Breast Reconstruction Using the Autologous Dermal Flap.
- Kaviani A, Ashraf-Ganjouei A, Vasigh M, Zand S, Patocskai E.
- J Surg Res. 2022 Nov 30;283:713-718. doi: 10.1016/j.jss.2022.11.002. Epub ahead of print.
- PMID: 36462381
- PubMed abstract
- Source abstract
- 3D CRISPR screen in prostate cancer cells reveals PARP inhibitor sensitization through TBL1XR1-SMC3 interaction.
- Zhang H, Gao H, Gu Y, John A, Wei L, Minhong Huang M, Yu J, Adeosun AA, Weinshilboum RM, Wang L.
- Front Oncol. 2022 Nov 29;12:999302. doi: 10.3389/fonc.2022.999302.
- [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a pilot study.
- Pantel AR, Gitto SB, Makvandi M, Kim H, Medvedv S, Weeks JK, Torigian DA, Hsieh CJ, Ferman B, Latif NA, Tanyi JL, Martin LP, Lanzo SM, Liu F, Cao Q, Mills GB, Doot RK, Mankoff DA, Mach RH, Lin LL, Simpkins F.
- Clin Cancer Res. 2022 Nov 28:CCR-22-1602. doi: 10.1158/1078-0432.CCR-22-1602. Epub ahead of print.
- PMID: 36441795
- PubMed abstract
- Source abstract
- Adolescent triple-negative breast cancer with germline pathogenic variants in both BRCA1 and TP53 genes: A case report.
- Chen D, Zhang C, Yuan M, Zhang Y, Liu Q, Wan D.
- Front Oncol. 2022 Nov 28;12:970641. doi: 10.3389/fonc.2022.970641.
- Case report
- Free Full Text
- Long-term response to olaparib in a patient with metastatic pancreatic cancer associated with hereditary breast and ovarian cancer syndrome.
- Tsuneizumi M, Terada S, Usui T, Yamaguchi K, Hayami R, Matsunuma R.
- Oxf Med Case Reports. 2022 Nov 24;2022(11):omac124. doi: 10.1093/omcr/omac124.
- PMID: 36447463
- PubMed abstract
- Case report
- Free PMC article
- Free Full Text